Estradiol/nomegestrol acetate as a first-line and rescue therapy for the treatment of ovarian and deep infiltrating endometriosis. (3rd July 2021)

• Record Type: Journal Article
• Authors: Mariani, Luca Liban; Novara, Lorenzo; Mancarella, Matteo; Fuso, Luca; Casula, Elisa; Biglia, Nicoletta
• Is Part Of: Gynecological endocrinology. Volume 37:Number 7(2021)
• Page Start: 646
• Page End: 649
• Publication Date: 2021-07-03
• Subjects: Endometriosis -- estradiol valerate/nomegestrol acetate -- ultrasonography; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2021.1903420
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: Purpose: Estradiol valerate/nomegestrol acetate (E2V/NOMAC) is a new combined oral contraceptive with a good tolerability profile and low drop-out rates, which was shown to improve menstrual-related symptoms. This study aims to evaluate its effectiveness in the control of symptoms and progression of disease in women with ovarian endomestriomas and deep infiltrating endometriosis (DIE). Methods: This was a retrospective cohort study on 39 women with pelvic endometriosis treated with E2V/NOMAC. We assessed for each patient, at the beginning of treatment and after 6 months, the painful symptoms, through a global VAS (Visual Analogue Scale) index and the size of the greatest ovarian and/or deep infiltrating endometriotic lesions. Results: After 6 months of treatment, a significant reduction was observed for the global VAS score for pain symptoms and for the mean size of ovarian endometriomas, whereas DIE lesions did not present significant changes in mean size. Conclusions: E2/NOMAC was effective in reducing pain symptoms associated with pelvic endometriosis and the size of ovarian endometriomas, whereas DIE lesions remained stable. This therapy could provide good results in the control of symptoms and disease progression in women with pelvic endometriosis.